178 related articles for article (PubMed ID: 32205863)
1. Immune phenotype and histopathological growth pattern in patients with colorectal liver metastases.
Stremitzer S; Vermeulen P; Graver S; Kockx M; Dirix L; Yang D; Zhang W; Stift J; Wrba F; Gruenberger T; Lenz HJ; Scherer SJ
Br J Cancer; 2020 May; 122(10):1518-1524. PubMed ID: 32205863
[TBL] [Abstract][Full Text] [Related]
2. Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
Stremitzer S; Stift J; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
Eur J Surg Oncol; 2015 Jul; 41(7):868-74. PubMed ID: 25865557
[TBL] [Abstract][Full Text] [Related]
3. Variations in genes involved in immune response checkpoints and association with outcomes in patients with resected colorectal liver metastases.
Stremitzer S; Sunakawa Y; Zhang W; Yang D; Ning Y; Stintzing S; Sebio A; Yamauchi S; Matsusaka S; El-Khoueiry R; Stift J; Wrba F; Gruenberger T; Lenz HJ
Pharmacogenomics J; 2015 Dec; 15(6):521-9. PubMed ID: 25752522
[TBL] [Abstract][Full Text] [Related]
4. Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.
Cremolini C; Milione M; Marmorino F; Morano F; Zucchelli G; Mennitto A; Prisciandaro M; Lonardi S; Pellegrinelli A; Rossini D; Bergamo F; Aprile G; Urbani L; Morelli L; Schirripa M; Cardellino GG; Fassan M; Fontanini G; de Braud F; Mazzaferro V; Falcone A; Pietrantonio F
Br J Cancer; 2018 Apr; 118(7):955-965. PubMed ID: 29531324
[TBL] [Abstract][Full Text] [Related]
5. Microscopic biliary and perineural invasion and clinical outcome after neoadjuvant bevacizumab-based chemotherapy and liver resection in patients with colorectal liver metastases.
Stift J; Graf A; Schwarz C; Tamandl D; Starlinger P; Herac M; Beer A; Wrba F; Bodingbauer M; Kaczirek K; Stremitzer S
Eur J Surg Oncol; 2018 Jan; 44(1):139-147. PubMed ID: 29203074
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer.
Turan N; Benekli M; Koca D; Ustaalioglu BO; Dane F; Ozdemir N; Ulas A; Oztop I; Gumus M; Ozturk MA; Berk V; Kucukoner M; Uner A; Balakan O; Helvaci K; Ozkan S; Yilmaz U; Buyukberber S;
Oncology; 2013; 84(1):14-21. PubMed ID: 23076023
[TBL] [Abstract][Full Text] [Related]
7. Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases.
Pietrantonio F; Mazzaferro V; Miceli R; Cotsoglou C; Melotti F; Fanetti G; Perrone F; Biondani P; Muscarà C; Di Bartolomeo M; Coppa J; Maggi C; Milione M; Tamborini E; de Braud F
Med Oncol; 2015 Jul; 32(7):182. PubMed ID: 26003673
[TBL] [Abstract][Full Text] [Related]
8. The Histopathological Growth Pattern of Colorectal Liver Metastases Impacts Local Recurrence Risk and the Adequate Width of the Surgical Margin.
Viganò L; Branciforte B; Laurenti V; Costa G; Procopio F; Cimino M; Del Fabbro D; Di Tommaso L; Torzilli G
Ann Surg Oncol; 2022 Sep; 29(9):5515-5524. PubMed ID: 35687176
[TBL] [Abstract][Full Text] [Related]
9. Growth pattern of colorectal liver metastasis as a marker of recurrence risk.
Eefsen RL; Vermeulen PB; Christensen IJ; Laerum OD; Mogensen MB; Rolff HC; Van den Eynden GG; Høyer-Hansen G; Osterlind K; Vainer B; Illemann M
Clin Exp Metastasis; 2015 Apr; 32(4):369-81. PubMed ID: 25822899
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy Plus Bevacizumab as Neoadjuvant or Conversion Treatment in Patients with Colorectal Liver Metastases.
García-Alfonso P; Cavanagh Podesta M; Muñoz Martín A; Blanco Codeisido M; Calvo A; Peligros I; Corcuera A; Belén Rúperez Blanco A; Custodio-Cabello S; López Trabada D; Martín M; DE Ramón E
Anticancer Res; 2018 May; 38(5):3069-3077. PubMed ID: 29715142
[TBL] [Abstract][Full Text] [Related]
11. Angiogenic desmoplastic histopathological growth pattern as a prognostic marker of good outcome in patients with colorectal liver metastases.
Galjart B; Nierop PMH; van der Stok EP; van den Braak RRJC; Höppener DJ; Daelemans S; Dirix LY; Verhoef C; Vermeulen PB; Grünhagen DJ
Angiogenesis; 2019 May; 22(2):355-368. PubMed ID: 30637550
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab improves survival in patients with synchronous colorectal liver metastases provided the primary tumor is resected first.
Lim C; Doussot A; Osseis M; Esposito F; Salloum C; Calderaro J; Tournigand C; Azoulay D
Clin Transl Oncol; 2018 Oct; 20(10):1274-1279. PubMed ID: 29594943
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations.
Passot G; Chun YS; Kopetz SE; Overman MJ; Conrad C; Aloia TA; Vauthey JN
Eur J Surg Oncol; 2016 Sep; 42(9):1378-84. PubMed ID: 27358198
[TBL] [Abstract][Full Text] [Related]
14. Preoperative systemic chemotherapy alters the histopathological growth patterns of colorectal liver metastases.
Nierop PM; Höppener DJ; Buisman FE; van der Stok EP; Galjart B; Balachandran VP; Jarnagin WR; Kingham TP; Shia J; Mauer M; Nordlinger B; Julié C; Groot Koerkamp B; Doukas M; Vermeulen PB; Grünhagen DJ; D'Angelica MI; Verhoef C
J Pathol Clin Res; 2022 Jan; 8(1):48-64. PubMed ID: 34480530
[TBL] [Abstract][Full Text] [Related]
15. CEA change after neoadjuvant chemotherapy including bevacizumab and clinical outcome in patients undergoing liver resection for colorectal liver metastases.
Stremitzer S; Stift J; Graf A; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
Ann Surg Oncol; 2015 Apr; 22(4):1315-23. PubMed ID: 25323471
[TBL] [Abstract][Full Text] [Related]
16. Replacement and desmoplastic histopathological growth patterns in cutaneous melanoma liver metastases: frequency, characteristics, and robust prognostic value.
Barnhill R; van Dam PJ; Vermeulen P; Champenois G; Nicolas A; Rawson RV; Wilmott JS; Thompson JF; Long GV; Cassoux N; Roman-Roman S; Busam KJ; Scolyer RA; Lazar AJ; Lugassy C
J Pathol Clin Res; 2020 Jul; 6(3):195-206. PubMed ID: 32304183
[TBL] [Abstract][Full Text] [Related]
17. A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases.
Chun YJ; Kim SG; Lee KW; Cho SH; Kim TW; Baek JY; Park YS; Hong S; Chu CW; Beom SH; Jung M; Shin SJ; Ahn JB
Clin Colorectal Cancer; 2020 Sep; 19(3):e140-e150. PubMed ID: 32402681
[TBL] [Abstract][Full Text] [Related]
18. Optimal indication criteria for neoadjuvant chemotherapy in patients with resectable colorectal liver metastases.
Ichida H; Mise Y; Ito H; Ishizawa T; Inoue Y; Takahashi Y; Shinozaki E; Yamaguchi K; Saiura A
World J Surg Oncol; 2019 Jun; 17(1):100. PubMed ID: 31196104
[TBL] [Abstract][Full Text] [Related]
19. Histopathological growth patterns of resected non-colorectal, non-neuroendocrine liver metastases: a retrospective multicenter study.
Meyer Y; Bohlok A; Höppener D; Galjart B; Doukas M; Grünhagen DJ; Labar A; Lucidi V; Vermeulen PB; Verhoef C; Donckier V
Clin Exp Metastasis; 2022 Jun; 39(3):433-442. PubMed ID: 35124739
[TBL] [Abstract][Full Text] [Related]
20. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
Vauthey JN; Zimmitti G; Kopetz SE; Shindoh J; Chen SS; Andreou A; Curley SA; Aloia TA; Maru DM
Ann Surg; 2013 Oct; 258(4):619-26; discussion 626-7. PubMed ID: 24018645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]